Designing a New Cyclic Peptide to Block TNFα Inflammation | Research

The takeaway

Computational design combined with NMR structural analysis produced a novel cyclopeptide that inhibits the TNFα-TNFR1 interaction involved in inflammatory diseases.

De novo
Cyclopeptide designed from scratch using computational methods to inhibit TNFα-TNFR1 interaction

What the researchers found

A computationally designed cyclopeptide successfully inhibits the TNFα-TNFR1 protein-protein interaction, validated by NMR structural analysis and biological activity assays.

Why it matters

TNFα inhibitors are among the most prescribed biologics worldwide but are expensive antibodies. A cyclopeptide alternative could offer a cheaper, more stable option for treating inflammatory diseases.

The numbers in context

NMR solution structure; computational design; TNF-alpha/TNFR-1 target; activity confirmed in sensor cells

How the study worked

Conformational analysis and molecular docking for design, solution-state NMR for structural confirmation, TNFα sensor cells for biological activity validation.

Who was studied

Synthetic cyclopeptide tested in TNF-alpha sensor cells

What this study cannot tell us

In vitro validation only. Biological activity assessed using sensor cells, not disease models. Pharmacokinetic properties and in vivo efficacy unknown.

How to read the evidence

Proof-of-concept with computational design validated by NMR and in vitro bioactivity. Very early stage with no disease model or clinical data.

When this study was published

Published in 2020. Represents the state of computational cyclopeptide design at that time.

The bigger picture

This study advances rational peptide drug design, showing computational methods can create biologically active cyclopeptides targeting therapeutically important protein interactions.

Questions still open

How does this cyclopeptide compare in potency to existing TNFα-blocking antibodies?
Can the cyclopeptide be optimized for oral bioavailability?
Would this design approach work for other protein-protein interactions?

Common questions

What makes cyclic peptides promising as drugs?

Cyclic peptides have a large surface area that can block protein-protein interactions that small molecule drugs cannot reach, while being more stable and potentially cheaper to produce than antibody drugs. Their circular structure makes them resistant to breakdown in the body.

Why target TNFα?

TNFα is a key inflammatory molecule that drives rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Current TNFα blockers are antibodies requiring injection and are expensive. A peptide alternative could reduce costs and improve accessibility.

Read the original research

Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide.

Molecules (Basel, Switzerland), 25(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Idress, Mohannad; Milne, Bruce F; Thompson, Gary S; Trembleau, Laurent; Jaspars, Marcel; Houssen, Wael E. (2020). Structure-Based Design, Synthesis and Bioactivity of a New Anti-TNFα Cyclopeptide.. Molecules (Basel, Switzerland), 25(4). https://doi.org/10.3390/molecules25040922